Novo Nordisk announced May 1 ↗ that its Ozempic ↗ pill (oral semaglutide ↗) will be available in more than 70,000 U.S. pharmacies starting Monday May 4, at 1.5 mg, 4 mg, and 9 mg dose strengths, for adults with type 2 diabetes. The product is the first FDA-approved oral peptide GLP-1 cleared for both primary and secondary cardiovascular risk reduction. Insured patients can access it for as little as $25 per three-month supply. Self-pay patients face $149 to $299 monthly through GoodRx-published tiers.
The launch lands three weeks after Eli Lilly's Foundayo (orforglipron) opened its commercial run on the obesity side. The IQVIA Week 3 read on Foundayo, also released May 1, was 5,612 prescriptions for the week ending April 24, up roughly 51% from Week 2's 3,707 and four times the Week 1 baseline. The trajectory is climbing. It is also still trailing the comparable third-week run of the Wegovy ↗ pill launch, the closest historical reference. RBC and other sell-side analysts continue to caution that 8 to 12 weeks of data are needed to read commercial signal through pharmacy-fill noise. On the Q1 earnings call, Lilly USA's Ilya Yuffa said roughly 20,000 patients are now on the drug for obesity or overweight, calling the early launch "encouraging."
The two products are structurally different. Semaglutide is a peptide GLP-1 receptor agonist, the same molecular architecture as injectable Ozempic and Wegovy, formulated for oral administration with the SNAC absorption enhancer. Orforglipron is a small-molecule GLP-1 receptor agonist, the first GLP-1 pill that is not a peptide ↗, as the news section covered on April 23. The clinical effect class is the same. The pharmacology, the manufacturing, and the regulatory file are different. The commercial implication is that the oral GLP-1 category, which did not really exist as a meaningful market until 2025, now has two distinct products in launch mode with different mechanism classes, different indications (T2D for Ozempic Pill, obesity for Foundayo), and different price architectures.
The channel layer is also new. WeightWatchers' Med+ platform announced May 1 that it will offer the Ozempic pill to clinically eligible T2D members at as low as $25 per month. GoodRx published self-pay tiers the same morning ($149 / $199 / $299 by dose strength). Both moves close transparency gaps that had dogged consumer access to oral GLP-1 therapy. The launch is multi-channel by design: traditional pharmacy distribution at 70,000 stores, telehealth platform integration through WW, and self-pay access through GoodRx. Comparison to the early oral semaglutide marketing under the Rybelsus ↗ brand is instructive. Rybelsus shipped through pharmacy alone, with the cardiovascular indication added later. Ozempic Pill ships with the cardiovascular label baked in and three channels live on day one.
What this changes commercially. The branded GLP-1 supply situation, which was the structural justification for the FDA's recent 503B compounding proposal ↗, is now meaningfully tighter on the access side. Patients who had been using compounded semaglutide for cost reasons can move to Ozempic Pill at $25 per month with insurance or $149 per month self-pay; the cost gap to compounded supply has narrowed considerably. Lilly's Q1 print yesterday set the high bar for May 6 Novo Q1 results; this morning's Ozempic Pill launch is the commercial counter-move that Novo has had ready for weeks. The combination of Lilly's pipeline (Mounjaro ↗, Zepbound ↗, Foundayo) and Novo's matching expansion (injectable Ozempic, Wegovy, oral Rybelsus, and now oral Ozempic) defines the second half of 2026 as the period when the GLP-1 category finally has real commercial competition between two well-supplied, multi-product franchises rather than a perpetual undersupply story.
The platform read. The GLP-1R ↗ target page on peptidemodel hosts the GLP-1(7-36) amide ↗ card that is the closest peptide reference for what the Ozempic pill delivers. Foundayo has no peptide card because it is not a peptide. The platform's design space, oriented toward peptide therapeutics, will continue to map cleanly onto Novo's portfolio while the Lilly portfolio diversifies into small-molecule GLP-1 territory that the platform's peptide focus does not directly cover.
Two open questions for the next 90 days. Whether Foundayo's prescription growth catches and surpasses the Wegovy-pill comparable curve as the launch matures, and whether Ozempic Pill volumes by Week 3 land closer to the Foundayo trajectory or substantially below given the different indication and patient population. The first comparison reads commercial execution. The second reads the pricing-versus-access elasticity in oral GLP-1, which the channel architecture announced today is built to optimize.